- Home
- GLMD vs THAR Comparison
GLMD vs THAR Comparison
Compare GLMD & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- THAR
- Stock Information
- Founded
- GLMD 2000
- THAR 2017
- Country
- GLMD Israel
- THAR United States
- Employees
- GLMD N/A
- THAR N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- THAR Health Care
- Exchange
- GLMD Nasdaq
- THAR Nasdaq
- Market Cap
- GLMD 3.0M
- THAR 3.3M
- IPO Year
- GLMD 2014
- THAR 2022
- Fundamental
- Price
- GLMD $1.81
- THAR $1.82
- Analyst Decision
- GLMD Hold
- THAR Strong Buy
- Analyst Count
- GLMD 1
- THAR 1
- Target Price
- GLMD N/A
- THAR $17.00
- AVG Volume (30 Days)
- GLMD 364.3K
- THAR 41.7K
- Earning Date
- GLMD 05-22-2025
- THAR 08-08-2025
- Dividend Yield
- GLMD N/A
- THAR N/A
- EPS Growth
- GLMD N/A
- THAR N/A
- EPS
- GLMD N/A
- THAR N/A
- Revenue
- GLMD N/A
- THAR N/A
- Revenue This Year
- GLMD N/A
- THAR N/A
- Revenue Next Year
- GLMD N/A
- THAR N/A
- P/E Ratio
- GLMD N/A
- THAR N/A
- Revenue Growth
- GLMD N/A
- THAR N/A
- 52 Week Low
- GLMD $1.15
- THAR $0.95
- 52 Week High
- GLMD $23.80
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- GLMD 61.13
- THAR 64.36
- Support Level
- GLMD $1.63
- THAR $1.30
- Resistance Level
- GLMD $1.94
- THAR $1.46
- Average True Range (ATR)
- GLMD 0.12
- THAR 0.14
- MACD
- GLMD 0.01
- THAR 0.02
- Stochastic Oscillator
- GLMD 69.77
- THAR 96.17
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.